Insmed (INSM) Misses Q4 EPS by 17c; Offers FY23 ARIKAYCE Revenue Guidance
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $126.29 -0.31%
EPS Growth %: +78.3%
Financial Fact:
Research and development: 23.43M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +78.3%
Financial Fact:
Research and development: 23.43M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.21), $0.17 worse than the analyst estimate of ($1.04). Revenue for the quarter came in at $59.3 million versus the consensus estimate of $63.57 million.
Insmed continues to expect full-year 2023 global revenues for ARIKAYCE to be between $285 million and $300 million.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
- Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
